Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Earnings for Esperion Therapeutics, Inc. (ESPR)
Earnings in 2023 (TTM): $-209,248,000
According to Esperion Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-209,248,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Esperion Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-209,248,000 | $-209,248,000 |
| 2022 | $-233,659,000 | $-287,817,000 |
| 2021 | $-269,108,000 | $-318,824,000 |
| 2020 | $-143,551,000 | $-166,189,000 |
| 2019 | $-97,165,000 | $-109,022,000 |
| 2018 | $-201,810,000 | $-201,810,000 |
| 2017 | $-166,988,000 | $-166,988,000 |
| 2016 | $-74,978,000 | $-74,978,000 |
| 2015 | $-49,784,000 | $-49,784,000 |
| 2014 | $-36,375,000 | $-36,375,000 |
| 2013 | $-26,088,133 | $-26,088,133 |
| 2012 | $-11,741,736 | $-11,741,736 |
| 2011 | $-10,817,341 | $-10,817,341 |
| 2002 | $-28,726,000 | $-28,726,000 |
| 2001 | $-24,931,000 | $-24,931,000 |
| 2000 | $-31,371,000 | $-27,576,000 |
| 1999 | $ | $-10,670,184 |